FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Neurokine Pharmaceuticals Inc.
1275 West 6th Avenue
Vancouver, BC V6H 1A6

Item 2: Date of Material Change

July 30, 2010

Item 3: News Release

A news releases were issued and disseminated on August 12, 2010 through Marketwire and subsequently filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

Neurokine Pharmaceuticals Inc. (NEUKF) by mutual agreement it rescinded a share subscription agreement with one of its shareholder and cancelled 4,000,000 shares of its previously issued common stock. Neurokine also raised another $40,000 in part through conversion of debt and issued 8,000,000 share and 5,000,000 warrants.

Item 5: Full Description of Material Change

See the news releases attached hereto as Exhibit “A”.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:
Ahmad Doroudian, President and CEO (604) 805-7783

Item 9: Date of Report

August 12, 2010

Exhibit “A”

Press Release

Neurokine Announces Cancellation of 4,000,000 Shares and Issuance of New Stock

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) – August 12, 2010 -- Neurokine Pharmaceuticals Inc. (NEUKF) is announcing that by mutual agreement it rescinded a share subscription agreement with one of its shareholder and cancelled 4,000,000 shares of its previously issued common stock.

Neurokine also raised another $40,000 in part through conversion of debt and issued 8,000,000 shares and warrants to purchase 5,000,000 shares. Neurokine issued 4,000,000 units to four investors at a price of $0.005 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share in the capital of Neurokine at an exercise price of $0.005 during the period of 2 years after the date of the issuance. Further, it issued 4,000,000 units to one investor at a price of $0.005 per unit, with each unit consisting of one share of common stock and a warrant to purchase one quarter of a share at an exercise price of $0.05 per share, exercisable during the period of 5 years.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Disclaimer

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the status of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to expand its operations, economic conditions in the industry and Neurokine's financial strength. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contacts:

Neurokine Pharmaceuticals Inc.
Ahmad Doroudian, Ph.D.
President and CEO
(604) 805-7783